This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Default Category
-
PerkinElmer - Developing Products in China for China
Sato, Vicki L.; Jaeker, Christoph; Reda, KareemCase HBS-612032-EService and Operations ManagementTo maximize their effectiveness, color cases should be printed in color. Sym-Bio, an entrepreneurial Chinese diagnostic company with a product line in infectious disease testing, has agreed to be acquired by PerkinElmer, an international corporation with businesses in neonatal testing, life science services, and environmental health. Sym-Bio wants to accelerate its growth and competitive position in China through this strategic move, and PerkinEl...Starting at €8.20
-
China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise, Teaching Plan
Sato, Vicki L.; Lobb, AnnelenaTeaching Note HBS-613103-ETeaching Plan for 612048.Starting at €0.00
-
China Novartis Institute for Biomedical Research: Building a sustainable, globally integrated research enterprise
Sato, Vicki L.; Jaeker, Christoph; Solanki, Pooja MehtaCase HBS-612048-ETo maximize their effectiveness, color cases should be printed in color. As the head of the Novartis Institute for Biomedical Research in China, En Li was shepherding a $1 billion R&D investment in China. So far he had been able to attract a large number of Chinese-born but US-trained scientists to play a critical role in establishing the site. How sustainable was this strategy, and what were the key things he had to do right to establish a globa...Starting at €8.20
-
BMS-Biocon Research Center: Growing a Joint Research Venture in India
Sato, Vicki L.; Chai, Sen; Ballenger, Rich; Chi, Christine; Down, Alexander; Leimberg, RossCase HBS-613072-EEntrepreneurshipBristol Myers Squibb, a multi-national pharmaceutical company, is seeking to globalize its R&D strategy while managing costs. It has formed a joint venture with an Indian company, which has worked well, but now faces a strategic decision on how and whether to continue.Starting at €8.20